ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Get Rating) reached a new 52-week high during trading on Monday . The stock traded as high as $52.23 and last traded at $48.09, with a volume of 73048 shares changing hands. The stock had previously closed at $39.14.
Analysts Set New Price Targets
Several research analysts recently commented on ANIP shares. Guggenheim raised their price target on shares of ANI Pharmaceuticals from $55.00 to $59.00 in a report on Tuesday. StockNews.com started coverage on shares of ANI Pharmaceuticals in a report on Thursday, March 16th. They issued a “hold” rating on the stock. Finally, HC Wainwright raised their price target on shares of ANI Pharmaceuticals from $53.00 to $60.00 in a report on Tuesday. One investment analyst has rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $55.67.
ANI Pharmaceuticals Price Performance
The company has a quick ratio of 2.40, a current ratio of 3.46 and a debt-to-equity ratio of 0.91. The company has a market capitalization of $777.18 million, a P/E ratio of -14.61 and a beta of 1.04. The business has a 50 day simple moving average of $39.71 and a 200-day simple moving average of $40.35.
Institutional Investors Weigh In On ANI Pharmaceuticals
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Global Alpha Capital Management Ltd. raised its stake in shares of ANI Pharmaceuticals by 3.0% during the first quarter. Global Alpha Capital Management Ltd. now owns 462,961 shares of the specialty pharmaceutical company’s stock valued at $18,389,000 after purchasing an additional 13,430 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in ANI Pharmaceuticals by 79.0% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,421 shares of the specialty pharmaceutical company’s stock worth $56,000 after acquiring an additional 627 shares in the last quarter. Ranger Investment Management L.P. raised its position in ANI Pharmaceuticals by 3.6% in the first quarter. Ranger Investment Management L.P. now owns 125,556 shares of the specialty pharmaceutical company’s stock worth $4,987,000 after acquiring an additional 4,370 shares in the last quarter. Barclays PLC raised its position in ANI Pharmaceuticals by 9.1% in the first quarter. Barclays PLC now owns 7,141 shares of the specialty pharmaceutical company’s stock worth $283,000 after acquiring an additional 595 shares in the last quarter. Finally, Jump Financial LLC bought a new stake in ANI Pharmaceuticals in the first quarter worth about $536,000. 67.89% of the stock is currently owned by institutional investors.
About ANI Pharmaceuticals
ANI Pharmaceuticals, Inc is a bio-pharmaceutical company, which engages in developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended release and combination products.
Featured Articles
- Get a free copy of the StockNews.com research report on ANI Pharmaceuticals (ANIP)
- How to Buy Southwest Airlines Stock
- Lucid Group Bottomed, But The Outlook Remains Cloudy
- Shoals Technology is an EV and Solar Play Just Getting Started
- Under Armour May Have Just Bottomed
- Skyworks Solutions: Another Crack in the Consumer Outlook
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
